Health economics of osteoporosis

被引：24

作者：

Borgstrom, Fredrik ^{[1
,2
]}

Kanis, John A. ^{[3
]}

机构：

[1] Karolinska Inst, Med Management Ctr, Stockholm 17177, Sweden

[2] i3 Innovus, SE-11120 Stockholm, Sweden

[3] Univ Sheffield, Sch Med, WHO Collaborating Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2008年 / 22卷 / 05期

关键词：

osteoporosis; fractures; health economics; cost-effectiveness;

D O I：

10.1016/j.beem.2008.07.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rather than reviewing the many studies of cost effectiveness in osteoporosis, this paper reviews the principles of cost-effectiveness analysis and the gaps in our knowledge that are required to improve such analyses in osteoporosis. These include more information on the cost of fractures and their consequences on health states, particularly on an international basis. New developments include the incorporation of adherence into models, the use of the FRAX (TM) tool to assess cost-effectiveness in individuals with any combination of risk factors for fracture, and the setting of intervention thresholds based on cost-effectiveness.

引用

页码：885 / 900

页数：16

共 55 条

[1]

BAGGER YZ, 2005, OSTEOPOROSIS INT, P1

[2] At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis [J].

Borgstroem, F. ;

Johnell, O. ;

Kanis, J. A. ;

Joensson, B. ;

Rehnberg, C. .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (10) :1459-1471

[3] An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting -: Based on the results of the SOTI and TROPOS trials [J].

Borgstrom, F. ;

Jonsson, B. ;

Strom, O. ;

Kanis, J. A. .

OSTEOPOROSIS INTERNATIONAL, 2006, 17 (12) :1781-1793

[4] A systematic review of health state utility values for osteoporosis-related conditions [J].

Brazier, JE ;

Green, C ;

Kanis, JA .

OSTEOPOROSIS INTERNATIONAL, 2002, 13 (10) :768-776

[5] Swedish population health-related quality of life results using the EQ-5D [J].

Burström, K ;

Johannesson, M ;

Diderichsen, F .

QUALITY OF LIFE RESEARCH, 2001, 10 (07) :621-635

[6] Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis [J].

Cranney, A ;

Tugwell, P ;

Adachi, J ;

Weaver, B ;

Zytaruk, N ;

Papaioannou, A ;

Robinson, V ;

Shea, B ;

Wells, G ;

Guyatt, G .

ENDOCRINE REVIEWS, 2002, 23 (04) :517-523

[7]

Czerwinski Edward, 2007, Ortop Traumatol Rehabil, V9, P337

[8] Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA [J].

Dawson-Hughes, B. ;

Tosteson, A. N. A. ;

Melton, L. J., III ;

Baim, S. ;

Favus, M. J. ;

Khosla, S. ;

Lindsay, R. L. .

OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :449-458

[9] Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam Study [J].

De Laet, CEDH ;

van Hout, BA ;

Burger, H ;

Weel, AEAM ;

Hofman, A ;

Pols, HAP .

OSTEOPOROSIS INTERNATIONAL, 1999, 10 (01) :66-72

[10] The cost of treating osteoporotic fractures in the United Kingdom female population [J].

Dolan, P ;

Togerson, DJ .

OSTEOPOROSIS INTERNATIONAL, 1998, 8 (06) :611-617

← 1 2 3 4 5 6 →